Newronika

Executive Summary

Newronika is a pioneering Italian medical device company specializing in adaptive deep brain stimulation (aDBS) systems. Founded in 2016 and headquartered in Milan, the company has developed the αDBS system, which is CE-marked and designed to provide real-time, closed-loop neuromodulation for Parkinson's disease. Unlike traditional DBS, Newronika's technology continuously adjusts stimulation based on the brain's own neural signals, potentially offering superior symptom control and fewer side effects. The company is now pursuing expansion into other neurological indications such as epilepsy and essential tremor.

Upcoming Catalysts (preview)

• Q2 2026FDA IDE approval for US pivotal trial in Parkinson's65% success
• Q4 2026Topline results from pilot study in epilepsy50% success
• Q3 2026Strategic partnership with a major neurotechnology firm for commercialization40% success